After billions of doses, science confirms the safety of mRNA vaccines

Introduction: the largest study ever conducted on this technology

A scientific verdict six years in the making

Six years after the start of the COVID-19pandemic, an international team of researchers led by the University of British Columbia has just published, in the prestigious journal The Lancet, the most comprehensive review ever conducted on the safety and effectiveness of messenger RNA vaccines, administered billions of times worldwide, according to detailed coverage published by UBC News on June 30, 2026.

This publication, released on June 30, 2026, doesn't merely confirm what the scientific community had already stated: it brings together, for the first time, the full body of laboratory data, clinical trials and real-world surveillance into a single rigorous synthesis.

Why this review arrives at a pivotal moment

This publication comes as disinformation around messenger RNA vaccines continues to circulate widely on social media, despite years of accumulated scientific data. The authors hope that the scale and rigor of this synthesis will help strengthen public confidence in the technology.

The effectiveness numbers that emerge from this synthesis

Strong protection against infection and hospitalization

According to data compiled in this review, messenger RNA vaccines proved 87% effective against documented SARS-CoV-2 infection, 93% effective against hospitalization, and 94% effective against death, within a window of 14 to 42 days following vaccination, according to Euronews coverage published on July 1, 2026.

These figures, obtained by cross-referencing randomized trials with field data collected over several years, confirm a robust effectiveness that held up across successive waves of variants, even though protection against infection tends to wane over time.

The effect of boosters and adaptation to variants

The review notes that booster doses restored much of the immunity lost over time, and that regular updates to the vaccine formulation kept effectiveness at a satisfactory level against emerging new variants, including Omicron and its sublineages.

Against the most recent forms of the virus, effectiveness against infection dropped to around 67% and to 72% against hospitalization in some analyses, a reminder that vaccine protection is never absolute, but remains statistically very significant.

The question of safety, at the heart of every debate

Serious side effects, but rare ones

On the question of safety, the review confirms that serious adverse events, such as myocarditis, pericarditis or anaphylaxis, remain extremely rare. The vast majority of reported reactions, such as pain at the injection site, fatigue or fever, stay mild to moderate and disappear within a few days.

The researchers stress that these rare effects are consistently outweighed by the substantial protection these vaccines provide against severe forms of the disease, hospitalization and death, a finding that holds even for the most vulnerable populations.

The specific case of myocarditis in young men

The risk of myocarditis, more common among young men, was precisely quantified in this review: roughly 12.6 cases per million doses for the Pfizer-BioNTech vaccine, and roughly 35.6 cases per million for the Moderna vaccine, according to data relayed by Reason magazine.

A crucial fact highlighted by the researchers: the risk of myocarditis associated with an actual COVID-19 infection is 20 to 42 times higher than the risk associated with vaccination itself, which puts this rare risk into essential perspective for any informed public health decision.

Protection that extends to the most vulnerable populations

Pregnant women and immunocompromised people, confirmed effectiveness

The review confirms that messenger RNA vaccines offer solid protection not only in the general population, but also among children, pregnant women and immunocompromised people, groups often excluded from initial clinical trials but now well documented through real-world surveillance data accumulated since 2020.

This extension of safety and effectiveness data to these vulnerable populations represents one of the most important contributions of this synthesis, filling a knowledge gap that historically fueled some legitimate vaccine hesitancy among these groups.

What this concretely changes for medical recommendations

These results reinforce existing recommendations from global health authorities in favor of vaccinating these populations, while giving healthcare professionals a much stronger evidence base to answer the legitimate questions their most vulnerable patients may have.

Dr. Manish Sadarangani, co-author of the review and director of the vaccine evaluation center at British Columbia's children's hospital, notes that this evidence base will help better support patients in their health decisions, with proof now consolidated over several years.

How this technology actually works, no mystery involved

No alteration of DNA, despite a persistent misconception

The review takes care to clarify a common point of confusion: messenger RNA vaccines do not in any way alter a person's DNA. The messenger RNA, encapsulated in a lipid nanoparticle system developed in part by researchers at UBC, provides temporary instructions that let human cells produce a harmless fragment of the virus, training the immune system to recognize it.

Another important clarification: the messenger RNA and lipid nanoparticles are rapidly broken down and eliminated by the body after use, a well-documented biological process that clearly distinguishes this technology from other forms of gene therapy with which it is sometimes wrongly confused.

An essential distinction from classic gene therapy

Researchers stress this fundamental distinction because part of the public's wariness toward these vaccines rests precisely on this confusion between temporary messenger RNA and permanent genetic modification, a confusion this review explicitly aims to dispel with explanations accessible to the general public.

This educational clarification, though technical, is essential to allow the public to make informed health decisions, grounded in a genuine understanding of the biological mechanism rather than in rumors circulating online.

Beyond COVID-19, an expanded therapeutic potential

Promising applications against other infectious diseases

The review notes that messenger RNA technology could, in the years ahead, find concrete applications against other infectious diseases, notably influenza and respiratory syncytial virus, often referred to by its acronym RSV, an area where several vaccine candidates are already in advanced clinical development.

These future applications would build on the same technological platform validated at scale during the pandemic, a considerable advantage in terms of development speed compared with traditional vaccine methods, which take longer to design and produce.

Cancer and autoimmune diseases, the next frontier

Even more striking, the authors discuss this technology's potential for treating cancer and autoimmune diseases, a rapidly expanding research field that could profoundly transform personalized medicine over the next decade, according to projections mentioned in the publication.

These prospects nonetheless remain at an earlier research stage than the already well-established infectious disease applications, and the authors themselves urge caution about realistic timelines before widespread clinical application in these new therapeutic areas.

What this review says about public trust and disinformation

An explicit goal of strengthening trust

The review's authors explicitly state that one of their goals is to strengthen public trust in this technology and to actively counter persistent disinformation, a phenomenon that continues to affect vaccination rates in several countries despite the abundance of reassuring data available.

This scientific communication ambition comes with an implicit acknowledgment that science alone isn't always enough to convince: how this information is communicated to the public matters just as much as its factual accuracy.

The challenge of equitable access to these technologies

Beyond trust, several experts cited by Euronews note that the main challenge for years to come is no longer so much proving the safety and effectiveness of these vaccines, now well established, but ensuring equitable access to this technology worldwide, particularly in low- and middle-income countries.

This question of equitable access remains one of the most persistent blind spots of the global response to pandemics, since even the most advanced technology is worthless if it never reaches the populations who need it most.

The limitations that the researchers themselves acknowledge

Long-term cellular immunity still needs deeper study

Despite this overwhelmingly positive assessment, the researchers acknowledge certain limitations of the current technology: messenger RNA vaccines are particularly effective at generating rapid antibody and memory B-cell responses, but remain less effective at producing long-lived plasma cells in the bone marrow, a factor that partly explains the decline in protection against infection over time.

This technical limitation is an active area of research for the next generations of messenger RNA vaccines, which could seek to improve the durability of the immune response without sacrificing the development speed that made this platform successful.

Scientific transparency worth highlighting

This explicit acknowledgment of the technology's current limitations, rather than presenting a uniformly positive picture, is itself a mark of scientific credibility for this review, avoiding the classic pitfall of overly enthusiastic and insufficiently nuanced medical popularization.

This methodological rigor, including the frank admission of persistent areas of uncertainty, should in my view strengthen rather than weaken this synthesis's credibility with a public sometimes wary of conclusions perceived as too uniformly favorable.

The Canadian context, a leading scientific role

UBC, a global pioneer in lipid nanoparticles

It's worth noting that the University of British Columbia is no secondary player in this story: researchers at this institution directly helped develop the lipid nanoparticle system that makes it possible to effectively deliver messenger RNA into the body, a major Canadian scientific contribution to a technology now deployed worldwide.

This expertise, built up over decades of fundamental research, partly explains why this institution was able to coordinate a synthesis of this scale, bringing together data from multiple countries and different health surveillance systems.

A legitimate scientific pride for Canada

This Canadian contribution to a medical advance of global importance deserves to be recognized and celebrated, at a time when funding for fundamental research is sometimes the subject of political debate over its short-term relevance, even as this example demonstrates precisely the value of long-term scientific investment.

This legitimate scientific pride should not, however, turn into blind triumphalism: the review itself calls for continued vigilance and further research to refine understanding of this promising but still evolving technology.

What this means for potential future pandemics

A now-proven technological platform

Beyond the retrospective assessment of COVID-19, this review confirms the strategic value of the messenger RNA platform for responding quickly to future pandemic threats, its accelerated development capability having already proven itself during the 2020 health crisis, an advantage considered crucial by experts in global health preparedness.

This rapid-response capability could prove decisive against future emerging pathogens, potentially more dangerous than SARS-CoV-2, where every week gained in vaccine development can translate into thousands of lives saved worldwide.

An investment in global health preparedness

This conclusion implicitly argues for maintaining, or even strengthening, public and private investment in this technological platform, rather than a post-pandemic disengagement that would deprive the world of a tool whose effectiveness has just been confirmed by the most rigorous scientific synthesis ever conducted on the subject.

Western governments, in particular, have an obvious strategic interest in continuing to support this field of research, which could prove to be one of the most effective lines of defense against future global health crises.

The scientific method behind this monumental synthesis

Six years of cross-checked and verified data

The authors, including Dr. Manish Sadarangani and Dr. Anna Blakney, analyzed published data covering the period from January 2020 to December 2025, cross-referencing laboratory research, randomized clinical trials and real-world surveillance, drawn primarily from the Pfizer-BioNTech and Moderna vaccines, the two main manufacturers that deployed this technology at global scale.

This multilayered methodological approach helps offset the limitations inherent to each type of data taken in isolation: clinical trials offer the rigor of experimental control, while real-world surveillance captures far more diverse populations and situations than the initial trials.

Peer review in one of the world's most demanding journals

The fact that this synthesis was published in The Lancet, one of the most prestigious and rigorous medical journals in the world for peer review, adds considerable scientific weight to its conclusions, since this type of publication requires a particularly high standard of evidence and methodology before acceptance.

This editorial rigor is an additional argument against voices that continue to cast doubt, without solid scientific grounding, on the widely documented safety and effectiveness of this vaccine technology.

Reactions from the international medical community

A largely favorable reception among public health experts

Health agencies such as the World Health Organization and the American Centers for Disease Control and Prevention welcomed this synthesis as further confirmation of data already accumulated since the mass rollout of messenger RNA vaccines in 2021.

Several professional societies in pediatrics, geriatrics and immunology also praised the methodological rigor of this review, noting that it reinforces an already well-established international scientific consensus on the issue.

Critical voices and their actual scientific weight

Some groups continue to dispute the legitimacy of these conclusions, often relying on isolated studies or flawed statistical interpretations, without ever managing to produce a counter-analysis of comparable methodological scale to the one published in The Lancet.

This asymmetry between the methodological solidity of the review and the fragility of the criticisms leveled against it deserves to be highlighted every time this debate resurfaces on social media or in certain outlets.

The economic and industrial impact of a validated technology

Pharmaceutical investment that keeps growing

The confirmation of the safety and effectiveness of messenger RNA vaccines encourages continued investment by Pfizer-BioNTech, Moderna and other pharmaceutical players in developing new applications of this technological platform, including against certain cancers and rare diseases.

These investments represent billions of dollars and tens of thousands of highly skilled jobs in biomedical research sectors across North America and Europe, an economic stake that goes well beyond the purely health-related question.

International competition in biotechnology

This scientific validation also strengthens the position of Western economies in the global race for cutting-edge biotechnology, at a time when powers such as China are investing massively in their own vaccine and biomedical research capabilities.

Maintaining scientific and industrial leadership in this strategic field is an issue that goes beyond simple public health, touching directly on the technological sovereignty of Western democracies.

What this review changes for future vaccination policies

Toward faster integration into vaccination schedules

Armed with this consolidated data, several national health authorities are considering integrating future generations of messenger RNA vaccines more quickly into their routine vaccination schedules, particularly for the highest-risk populations such as elderly and immunocompromised people.

This shift could considerably speed up the response to future health threats, whether new variants of SARS-CoV-2 or entirely new pathogens capable of triggering a future pandemic.

The need for renewed public education

The review's authors stress the importance of translating these complex scientific results into language accessible to the general public, an essential condition for this accumulation of evidence to genuinely translate into greater trust in the technology.

This education effort will have to compete with an information environment saturated with disinformation, where a rigorous study running hundreds of pages must compete with viral posts built on fear and anecdote rather than scientific evidence.

Conclusion: a mature science that must now convince

A scientific case now firmly established

This review published in The Lancet probably represents the culmination of six years of accumulated data on messenger RNA vaccines, confirming their safety, their effectiveness and their potential for expansion into new therapeutic fields, from cancer to autoimmune diseases to future emerging infectious diseases.

At this stage, the scientific case appears as solid as it can reasonably be for a relatively recent medical technology, with billions of doses administered and documented worldwide.

The challenge that remains ahead, trust and access

The scientific battle appears largely won; what remains is the battle for public trust and equitable access to this technology, two challenges that depend less on fundamental research than on scientific communication, public health policy and international solidarity with countries least well equipped in health infrastructure.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my acknowledged biases

I am a columnist, not a physician or an immunology researcher. This analysis draws on coverage of the review published in The Lancet by UBC News, Euronews, CIDRAP, Reason Magazine and CBC, all cited in the sources below. My acknowledged bias favors vaccination and evidence-based medicine, while I strive to faithfully report the nuances and limitations that the researchers themselves acknowledge in their own work.

I make no miracle-cure promises about the future applications discussed, such as cancer treatment, which remain at an earlier research stage than the already well-established infectious disease applications.

What I don't know

I do not have the complete scientific article published in The Lancet with the full set of its detailed statistical data, only its coverage by several reliable specialized outlets. I have not invented any data or testimony: all information reported comes directly from the sources cited below.

Sources

Primary sources

UBC News, Billions of doses later: Global review confirms mRNA vaccines are safe, effective and full of promise — June 30, 2026

PubMed, Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective, The Lancet — June 30, 2026

Secondary sources

Euronews, Billions of mRNA vaccine doses' review underpins their effectiveness — July 1, 2026

CIDRAP, Comprehensive review affirms COVID mRNA vaccines are safe, effective — July 1, 2026

Reason Magazine, New study of billions of mRNA vaccine shots confirms their safety and efficacy — July 1, 2026

CBC News, mRNA vaccines proved safe and effective during COVID, review confirms — July 1, 2026